Triple Combination Drug for Hypertension and Dyslipidemia Based on Kanarb

Boryung announced on May 28 that it will launch "Kanavjet," a triple-combination drug for hypertension and dyslipidemia, on June 1. Kanavjet is a combination drug that merges the Korean-developed antihypertensive agent "Kanarb" (fimasartan) with atorvastatin and ezetimibe.


The launch symposium of Boryung's triple-combination drug for hypertension and dyslipidemia, 'Kanabjet,' held on the 21st. Boryung

The launch symposium of Boryung's triple-combination drug for hypertension and dyslipidemia, 'Kanabjet,' held on the 21st. Boryung

View original image

Kanavjet is a product that combines fimasartan, an angiotensin II receptor blocker (ARB), with atorvastatin, a statin, and ezetimibe, a cholesterol absorption inhibitor. It is mainly prescribed for patients with both hypertension and dyslipidemia, as well as high-risk patients who have not reached their LDL cholesterol targets with statin monotherapy alone.


Boryung explained that the launch reflects the current prescribing trend emphasizing integrated management of chronic diseases and early combination therapy. The company also pointed out that approximately 72% of hypertension patients in Korea also have dyslipidemia.


Boryung held a symposium on May 21 to commemorate the launch of Kanavjet, where it introduced treatment strategies for managing both hypertension and dyslipidemia, as well as ways to utilize combination drugs.


Professor Lee Chanju from the Department of Cardiology, Yonsei University College of Medicine, stated, "Fimasartan is an ingredient whose safety and efficacy have been confirmed in various patient groups, based on its high receptor binding affinity and long-lasting blood pressure-lowering effect." He added, "As guidelines are shifting towards recommending early treatment of hypertension and dyslipidemia and the combination of statin and ezetimibe, active control of blood pressure and LDL cholesterol can help reduce the risk of cardiovascular disease."


Since the launch of Kanarb in 2011, Boryung has been expanding its "Kanarb Family" line of combination products. The company is currently developing a four-drug combination based on Kanarb, as well as combination therapies for hypertension and diabetes.



Seong Baekmin, Executive Vice President and Head of BD & Marketing Division at Boryung, stated, "With the launch of Kanavjet, we can offer more diverse treatment options to healthcare professionals and patients." He added, "Based on clinical data from Kanarb, we will strengthen our efforts to target the hypertension and dyslipidemia treatment market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing